Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Freeing Parkinson’s patients from depressive symptoms

Freeing Parkinson’s patients from depressive symptoms

Stories Apr 14, 2023 3 minutes

A novel therapy shows signs that it could provide relief of major depression among patients with Parkinson’s disease.

A novel technique used to treat depression has shown promise as a means of helping relieve some of the symptoms of Parkinson’s disease, according to the preliminary findings of the ongoing Magnetic Seizure Therapy (MST) for Parkinson’s Disease clinical trial. 

“Parkinson’s affects parts of the frontal cortex that modulate mood and energy levels, among other areas of the autonomic nervous system,” explains study lead, Vancouver Coastal Health Research Institute researcher Dr. Fidel Vila-Rodriguez. 

“The brain is like a road, in that an accident in one area can lead to downstream impacts in other areas.” 

While Parkinson’s disease initially affects dopamine cells in the brain stem that lead to motor symptoms, over time several other parts of the brain are impacted, including areas that influence mood, anxiety or energy. A progressive brain disorder, symptoms often worsen with time.

Many symptoms of Parkinson’s mirror those of depression, including apathy, sleep difficulties, decreased motor activity, a lack of enjoyment in activities and a sad demeanour visible in facial expressions. 

Up to 50 per cent of Parkinson’s patients are diagnosed with depression, and many receive little benefit from traditional antidepressants.

“It is hard to disentangle whether a patient’s depression symptoms result from dopamine deficits in Parkinson’s disease or other reasons,” explains Vila-Rodriguez. “However, we know that dopamine uptake medication is often not an effective treatment for depressive symptoms.” 

Magnetic seizure therapy had mood-boosting effects on one study participant

Vila-Rodriguez and his research team theorize that MST technology could help ameliorate several of the symptoms of Parkinson’s disease, including anxiety and depressive symptoms. 

The MST procedure involves applying coil-shaped, electrically charged magnets to the forehead area of a patient to target the frontal cortex of their brain. The procedure triggers a controlled seizure that lasts less than one minute.

Brain activity during the MST procedure.

“This focal seizure becomes generalized and spreads to the rest of the brain, which we believe may regulate not only the dopamine circuits that are primarily responsible for motor symptoms but also other areas that regulate mood symptoms,” says Dr. Fidel Vila-Rodriguez.

The setup of the MST machine with coil-shaped electromagnetic applicator and LCD screen monitoring data displays.

Participants in Vila-Rodriguez’s clinical trial receive treatment twice per week for up to 16 treatments. To be eligible, participants must be 50 years of age or older, and have a diagnosis of both Parkinson’s and depression. 

Fidel Vila-Rodriguez is the director of the NINET Laboratory at the University of British Columbia (UBC). He is also the director of the Schizophrenia Program, an assistant professor in the Department of Psychiatry and an associate member in the School of Biomedical Engineering at UBC.

Before participating in the clinical trial, one study participant experienced prolonged major depression that involved withdrawal from his family and a disinterest in seeing his grandchildren, both of which he had a prior fondness.

“The patient shared that he is now getting out more and enjoying activities again,” explains Vila-Rodriguez. “He is smiling, cracking jokes and spending more time with his grandkids and other family members.”

“After receiving the therapy, the patient reported feeling decreased levels of anxiety and a greater sense of relaxation.”

He also had previous difficulties getting up to use the washroom at night, dressing and feeling comfortable leaving his home to attend appointments, often requiring assistance and reassurance from his wife. Following the MST procedure, all three are now manageable enterprises. 

“This result was noticeable and tangible to both the patient and his wife,” adds Vila-Rodriguez. “It has substantially improved their quality of life with no real side effects to speak of.”

The Magnetic Seizure Therapy for Parkinson’s Disease clinical trial is currently recruiting patient participants. To learn more, contact study coordinator Michelle Avina at 604-827-1361 or ninet.lab@ubc.ca.

Researchers

Fidel Vila-Rodriguez

Related Articles

More equitable representation needed in Parkinson’s research

AI innovation puts VCHRI scientist at the forefront of global drug discovery avenues

Eye movements could be a window into brain health and function

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy